Archive by Tag: doctors

Not Enough Doctors?

Industry Insights from Paul Meade, M.Sc, MPH Recently, I read a Wall Street Journal op-ed piece titled “Why the Doctor Can’t See You” by John Goodman, President of the National Center for Policy Analysis.  The central point of Goodman’s piece[...]

Thought Leader Select Announces New KOL Identification and Profiling Projects in Oncology, Neurology

Thought Leader Select is pleased to announce a series of key opinion leader (KOL) identification and profiling projects to support multiple therapeutic areas for a top five global biopharmaceutical company. In these research assessments, Thought Leader Select will identify and[...]

Thought Leader Select Announces New Assessments of Key Opinion Leaders, Centers of Excellence in Women’s Health, Oncology

Company News Thought Leader Select is pleased to announce a pair of projects in support of a top 10 global biopharmaceutical company as it seeks to develop a portfolio of medicines in women’s health. For the assessments, Thought Leader Select[...]

Should Doctors Be Paid By Drug Companies?

Industry Insights from Paul Meade, M.Sc., MPH Should doctors be paid by drug companies? Well, I guess that depends on the reason for the payment. If a physician, known for her expertise in a given area, is asked by a[...]

Successful Product Launches with the Right Thought Leaders

Industry Insights from Paul Meade, M. Sc, MPH When a biopharmaceutical company introduces a new medicine to the market, it comes after years of research, years of clinical development, and some times even years of regulatory review. With the patent[...]

The Illuminating Value of a Key Opinion Leader Research Assessment: Validation versus Identification

During a recent client feedback survey interview, a pharmaceutical company executive defined Thought Leader Select’s value in this manner:  “We always think we know our physician key opinion leaders in a given therapeutic area.  Your company provides immense value not[...]

The Trifecta of Mutually-Beneficial Relationships: KOLs, Pharma, and Patients—Part Four

Pharmaceutical & Biotechnology Companies Provide Early Knowledge-building Opportunities for KOLs and Clinical Investigators Understanding the value that key opinion leaders provide pharmaceutical and biotechnology companies is clear, but how do companies benefit thought leaders and clinical investigators? By definition, KOLs[...]